Stem Cell Transplant vs. Stem Cell Therapy: Why These Very Different Treatments Get Confused

What This Article Covers

Two treatments share the words “stem cell” and almost nothing else. A hematopoietic stem cell transplant (HSCT) — what most people mean by “bone marrow transplant” — is a rigorously studied, FDA-recognized standard of care that has helped treat leukemia, lymphoma, and other blood disorders for decades. “Stem cell therapy” as sold at many wellness and orthopedic clinics usually means an injection of mesenchymal stem cells (MSCs) for joint pain, autoimmune disease, anti-aging, or neurological conditions — and for nearly all of those uses, it is not FDA-approved and has a thin, often low-quality evidence base. This article explains what each treatment actually is, why the evidence behind them is so different, and why mixing them up can lead patients to take on serious risk for something the transplant field's decades of success were never actually about.

What a Stem Cell Transplant Actually Is

A hematopoietic stem cell transplant replaces a patient's blood-forming stem cells — the cells in bone marrow that become red blood cells, white blood cells, and platelets — after those cells have been wiped out by high-dose chemotherapy or radiation. In an autologous transplant, the patient's own stem cells are collected beforehand and given back; in an allogeneic transplant, the cells come from a matched donor, ideally a close relative or a match found through a registry. According to the National Cancer Institute, HSCT is standard treatment for blood cancers including leukemia, lymphoma, and multiple myeloma, as well as myelodysplastic syndromes, aplastic anemia, and sickle cell disease. This is not a fringe or experimental idea: NMDP (formerly Be The Match), the nonprofit that operates the U.S. donor registry, facilitated its 150,000th transplant this year — reaching that milestone less than six years after its first 100,000, a sign of how routine and scaled this medicine has become. NMDP also reports that 99% of adult patients with common blood cancers can now be matched to a suitable donor or cord blood unit through its network of more than 43 million registered donors worldwide. This is genuinely good news, decades in the making, for people who once had no options.

What “Stem Cell Therapy” Usually Means at a Clinic

When a clinic advertises “stem cell therapy” for a bad knee, back pain, an autoimmune condition, or general “anti-aging,” it is almost never talking about a bone marrow transplant. It typically means an injection of mesenchymal stem cells — sometimes harvested from a patient's own fat or bone marrow, sometimes from amniotic or umbilical cord tissue products — directly into a joint, spine, or bloodstream. The FDA has been direct about this category: in its consumer alert on regenerative medicine products, the agency states that patients “may be misled by information about products that are illegally marketed” and not shown to be safe or effective. Critically, the FDA notes that the only currently approved stem cell products are blood-forming stem cells derived from umbilical cord blood, and only for blood-related disorders — not for orthopedic, neurological, autoimmune, or cosmetic use. Nearly everything sold under the “stem cell therapy” banner for those conditions falls outside that approval.

Why the Evidence Bases Are So Different

HSCT has been refined since the first successful transplants in the 1950s–1970s, studied in large multicenter trials, and is tracked in real time by CIBMTR, a research collaboration between the National Marrow Donor Program and the Medical College of Wisconsin that maintains outcomes data on hundreds of thousands of transplant patients. Its risks, success rates, and appropriate uses are documented condition-by-condition. Clinic-based MSC injections generally have no comparable body of evidence. Many are offered under a legal gray area, sold as same-day procedures using a patient's own tissue, with claims built on small uncontrolled studies, animal data, or marketing rather than large randomized trials. The FTC has taken enforcement action against stem cell marketers for exactly this gap between claims and evidence, warning consumers in 2021 that “stem cell products have not been shown to be safe or effective for most ailments” and that testimonials on clinic websites are not proof of anything.

Real Risks on Both Sides — But Different Ones

None of this means HSCT is risk-free — it is one of the more grueling treatments in medicine. Conditioning chemotherapy and radiation cause significant short-term side effects, and allogeneic transplant carries the risk of graft-versus-host disease, a potentially serious complication in which donor immune cells attack the recipient's own tissues, per the NCI. Transplant teams manage these risks because the alternative, for many blood cancer patients, is often no treatment option at all — and the tradeoff has been studied exhaustively. Unproven clinic stem cell therapy carries a different, often under-disclosed risk profile: because products and injection sites aren't standardized or FDA-reviewed for safety and purity, the FDA has documented adverse events including infections, tumors, blindness, and in at least one case tied to an unapproved injectable tissue product, a patient death. The danger isn't that clinic MSC injections are automatically as risky as a transplant — it's that patients are often told far less about the risks they are actually taking on.

Bottom Line

“Stem cell transplant” and “stem cell therapy” are not two names for the same idea — they are two different treatments, built on two very different foundations of evidence, regulation, and risk disclosure. Hearing that transplants save lives in leukemia is true and worth celebrating; assuming that same evidence backs an injection at a wellness clinic is the mistake worth avoiding. Anyone considering either should ask plainly what is being injected or infused, what FDA approval (if any) applies to it, and what data — not testimonials — supports it for their specific condition.